The predominance of Alzheimer’s disease (AD) among the aged remains a global challenge. As such, the search for alternative and effective therapeutic options continuous unabated. Among the therapeutic targets explored over the years toward impeding the progression of AD is caspase-6 (Casp6), although selectively targeting Casp6 remains a challenge due to high homology with other members of the caspase family. Methyl 3-[(2,3-dihydro-1-benzofuran-2-yl formamido) methyl]-5-(furan-2-amido) benzoate (C13), a novel allosteric inhibitor, is reportedly shown to exhibit selective inhibition against mutant human Casp6 variants (E35K). However, structural and atomistic insights accounting for the reported inhibitory prowess of C13 remains unresolved. In this study, we seek to unravel the mechanistic selectivity of C13 coupled with the complementary effects of E35K single-nucleotide polymorphism (SNP) relative to Casp6 inhibition. Analyses of binding dynamics revealed that the variant Lysine-35 mediated consistent high-affinity interactions with C13 at the allosteric site, possibly forming the molecular basis of the selectivity of C13 as well as its high binding free energy as estimated. Analysis of residue interaction network around Glu35 and Lys35 revealed prominent residue network distortions in the mutant Casp6 conformation evidenced by a decrease in node degree, reduced number of edges and an increase short in path length relative to a more compact conformation in the wild system. The relatively higher binding free energy of C13 coupled with the stronger intermolecular interactions elicited in the mutant conformation further suggests that the mutation E35K probably favours the inhibitory activity of C13. Further analysis of atomistic changes showed increased C-α atom deviations consistent with structural disorientations in the mutant Casp6. Structural Insights provided could open up a novel paradigm of structure-based design of selective allosteric inhibition of Casp6 towards the treatment of neurodegenerative diseases.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Deepak, K. (2018). Identification of FDA-approved drugs as novel allosteric inhibitors of human executioner caspases. Proteins, 86(11), 1202–1210.
Behzadi, P. (2015). Caspases and apoptosis. iMedPub Journal, 1(2), 6.
MacKenzie, S. H., Schipper, J. L., & Clark, A. C. (2010). The potential for caspases in drug discovery. Current Opinion in Drug Discovery and Development, 13(5), 568–576.
Howley, B., & Fearnhead, H. O. (2008). Caspases as therapeutic targets. Journal of Cellular and Molecular Medicine, 12(5A), 1502–1516.
Garrido, E. R., Heidt, L., Beaubier, N., & Troy, C. M. (2011). Neurochemical mechanisms in disease. Advances in Neurobiology 1, Springer New York, chapter 2, 17–47.
Martinon, F., & Tschopp, J. (2004). Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell, 117(5), 561–574.
Fang, H., Chen, C., Hung, M., Hsiao, Y., & Chiang, T. (2011). Caspase-14 is an anti-apoptotic protein targeting apoptosis-inducing factor in lung adenocarcinomas. Oncology Reports, 26(2), 359–369.
McIlwain, D. R., Berger, T., & Mak, T. W. (2013). Caspase functions in cell death and disease. Cold Spring Harbor Perspectives in Biology, 5(4), a008656.
Baumgartner, R., et al. (2009). The crystal structure of caspase-6, a selective effector of axonal degeneration. Biochemical Journal, 423(3), 429–439.
Guo, H., Albrecht, S., Bourdeau, M., Petzke, T., Bergeron, C., & LeBlanc, A. C. (2004). Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer’s disease. The American Journal of Pathology, 165(2), 523–531.
Leblanc, A. C. (2011). Caspase-6 activation in familial Alzheimer disease brains carrying amyloid precursor protein, presenilin I or presenilin II mutations. Journal of Neuropathology and Experimental Neurology, 68(12), 1282–1293.
Tubeleviciute-Aydin, A., et al. (2019). Identification of allosteric inhibitors against active caspase-6. Scientific Reports, 9(1), 1–19.
Yang, J., et al. (2018). Mechanism of gasdermin D recognition by inflammatory caspases and their inhibition by a gasdermin D-derived peptide inhibitor. Proceedings of the National Academic Sciences of the USA, 115(26), 6792–6797.
Pettersen, E. F., et al. (2004). UCSF chimera—a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612.
ChemAxon. (2015). MarvinSketch user’s guide. https://chemaxon.com/products/marvin.
Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeersch, T., Zurek, E., & Hutchison, G. R. (2012). Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics, 4, 7.
Trott, O., & Olson, A. (2010). NIH public access. Journal of Computational Chemistry, 31(2), 455–461.
Ncube, N. B., Ramharack, P., & Soliman, M. E. S. (2018). An ‘All-In-One’ pharmacophoric architecture for the discovery of potential broad-spectrum anti-flavivirus drugs. Applied Biochemistry and Biotechnology, 185(3), 799–814.
Munsamy, G., Agoni, C., & Soliman, M. E. S. (2018). A dual target of Plasmepsin IX and X: unveiling the atomistic superiority of a core chemical scaffold in malaria therapy. Journal of Cellular Biochemistry, 120(5), 7876–7887.
Agoni, C., Ramharack, P., & Soliman, M. E. S. (2018). Synergistic interplay of the co-administration of rifampin and newly developed anti-TB drug: could it be a promising new line of TB therapy? Combinatorial Chemistry and High Throughput Screening, 21(6), 453–460.
Olotu, F. A., Agoni, C., Adeniji, E., Abdullahi, M., & Soliman, M. E. (2018). Probing gallate-mediated selectivity and high-affinity binding of epigallocatechin gallate: a way-forward in the design of selective inhibitors for anti-apoptotic Bcl-2 proteins. Applied Biochemistry and Biotechnology, 187(3), 1061–1080.
Agoni, C., Ramharack, P., & Soliman, M. (2018). Co-inhibition as a strategic therapeutic approach to overcome rifampin resistance in tuberculosis therapy: atomistic insights. Future Medicinal Chemistry, 10(4), 1665–1675.
Agoni, C., Ramharack, P., & Soliman, M. E. S. (2018). Allosteric inhibition induces an open WPD-loop: a new avenue towards glioblastoma therapy. RSC Advances, 8(70), 40187–40197.
Ramharack, P., & Soliman, M. E. S. (2016). Zika virus drug targets: a missing link in drug design and discovery—a route map to fill the gap. RSC Advances, 6(73), 68719–68731.
Salomon-ferrer, R., Case, D. A., & Walker, R. C. (2012). An overview of the Amber biomolecular simulation package. WIRES Computational Molecular Science, 3(2), 198–210.
Case, D. A., Babin, V., Berryman, J., Cai, R. M., Betz, Q., Cerutti, D. S., Cheatham III, T. E., Darden, T. A., Duke, R. E., & Gohlke, H., AMBER (2018).
Maier, J. A., Simmerling, C., Wickstrom, L., Hauser, K. E., Martinez, C., & Kasavajhala, K. (2015). ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8), 3696–3713.
Case, D. A., et al. (2005). The Amber biomolecular simulation programs. Journal of Computational Chemistry, 26(16), 1668–1688.
Péronnet, F., et al. (2012). Pharmacokinetic analysis of absorption, distribution and disappearance of ingested water labeled with D2O in humans. European Journal of Applied Physiology, 112(6), 2213–2222.
Seifert, E. (2014). OriginPro 9.1: scientific data analysis and graphing software—software review. Journal of Chemical Information and Modeling, 54, 1552.
Pitera, J. W. (2014). Expected distributions of root-mean-square positional deviations in proteins. The Journal of Physical Chemistry B, 118(24), 6526–6530.
Maiorov, V. N., & Crippen, G. M. (1994). Significance of root-mean-square deviation in comparing three-dimensional structures of globular proteins. Journal of Molecular Biology, 235(2), 625–634.
Doncheva, N. T., Klein, K., Domingues, F. S., & Albrecht, M. (2011). Analyzing and visualizing residue networks of protein structures. Trends in Biochemical Sciences, 36(4), 179–182.
Xue, W., Jin, X., Ning, L., Wang, M., Liu, H., & Yao, X. (2012). Exploring the molecular mechanism of cross‐resistance to HIV‐1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. Journal of Chemical Information and Modeling, 53, 210–222.
Roe, D. R., & Cheatham, III, T. E. (2013). PTRAJ and CPPTRAJ: software for processing and analysis of molecular synamics trajectory data. Journal of Chemical Theory and Computation, 9(7), 3084–3095.
Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449–461.
Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10, 449–461.
Mhlongo, N. N., & Soliman, M. E. S. (2015). Single H5N1 influenza A neuraminidase mutation develops resistance to oseltamivir due to distorted conformational and drug binding landscape: multiple molecular dynamics analyses. RSC Advances, 5(14), 10849–10861.
Ndagi, U., Mhlongo, N. N., & Soliman, M. E. (2017). The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design. Molecular BioSystems, 13(6), 1157–1171.
Oguntade, S., Ramharack, P., & Soliman, M. E. (2017). Characterizing the ligand-binding landscape of Zika NS3 helicase-promising lead compounds as potential inhibitors. Future Virology, 12(6), 261–273.
Moonsamy, S., Bhakat, S., Walker, R. C., & Soliman, M. E. S. (2016). Single active site mutation causes serious resistance of HIV reverse transcriptase to lamivudine: insight from multiple molecular dynamics simulations. Cell Biochemistry and Biophysics, 74(1), 35–48.
Kumalo, H. M., & Soliman, M. E. (2016). Per-residue energy footprints-based pharmacophore modeling as an enhanced in silico approach in drug discovery: a case study on the identification of novel β-Secretase1 (BACE1) inhibitors as anti-Alzheimer agents. Cellular and Molecular Bioengineering, 9(1), 175–189.
The authors acknowledge the School of Health Science, University of KwaZulu-Natal, Westville campus for financial assistance, and The Centre of High Performance Computing (CHPC, www.chpc.ac.za), Cape Town, RSA, for computational resources.
Conflict of Interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kumi, R.O., Agoni, C., Issahaku, A.R. et al. ‘Polymorphism-aided’ Selective Targeting and Inhibition of Caspase-6 by a Novel Allosteric Inhibitor Towards Efficient Alzheimer’s Disease Treatment. Cell Biochem Biophys (2020). https://doi.org/10.1007/s12013-020-00927-0
- Single-nucleotide polymorphism
- Putative allosteric site
- Alzheimer’s disease
- Selective targeting